文献速递造血干细胞移植与细胞治疗

氯倍他索溶液治疗口腔慢性移植物抗宿主病的随机2期安慰剂对照试验

A randomized phase 2 placebo-controlled trial of clobetasol solution for oral chronic graft-versus-host disease therapy.
PubMed 文献 · Blood Adv · 2026-09-25

该随机双盲安慰剂对照2期试验评估0.05%氯倍他索溶液治疗口腔慢性移植物抗宿主病(cGVHD)的安全性和疗效,主要终点为28天时。40例随机受试者中35例达到第28天,完全缓解率19%、部分缓解率72%、疾病稳定9%,总缓解率91%。氯倍他索溶液耐受性良好,但第28天促肾上腺皮质激素测试显示14例既往未接受超生理剂量糖皮质激素的患者出现新发肾上腺皮质功能不全。

要点

  • 0.05%氯倍他索口腔溶液在口腔cGVHD中总缓解率达91%(CR 19%,PR 72%)。
  • 安慰剂对照阶段氯倍他索组临床疾病和口腔疼痛改善更明显。
  • 第28天14例患者出现新发肾上腺皮质功能不全,需监测皮质醇。

核心结论

  • 0.05%氯倍他索口腔溶液治疗口腔cGVHD临床有效,并诱导可测量的组织水平免疫学变化。

研究设计与样本

  • 随机、双盲、安慰剂对照2期临床试验,共随机40例受试者,35例达到第28天主要终点评估。

主要发现

  • 第28天时19%达完全缓解,72%达部分缓解,9%疾病稳定,总缓解率91%。
  • 14天安慰剂对照阶段,氯倍他索组临床疾病和口腔疼痛改善大于安慰剂组。
  • 第28天促肾上腺皮质激素测试显示14例既往未接受超生理剂量糖皮质激素的患者出现新发肾上腺皮质功能不全。
  • 基线和第28天配对口腔黏膜活检显示所有T细胞(包括效应和增殖T细胞)频率降低,胞质IL-17非T细胞减少,唾液IL-6和CXCL10降低。

临床怎么用

  • 0.05%氯倍他索口腔溶液可用于口腔cGVHD局部治疗,包括氯倍他索软膏治疗失败的患者。
  • 治疗期间需通过促肾上腺皮质激素测试监测肾上腺皮质功能,警惕新发肾上腺皮质功能不全。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic graft-versus-host disease (cGVHD) affects multiple organ systems and frequently the mouth. There is an unmet need for more effective topical therapy to adequately control cGVHD in the oral cavity. Clobetasol is a super-potent synthetic glucocorticoid formulated here as an oral solution in an aqueous base (clobetasol solution) to enhance mucosal coverage and steroid delivery. We conducted a randomized, double-blind, placebo-controlled phase 2 clinical trial to evaluate the safety and efficacy of clobetasol 0.05% solution at 28 days of clobetasol treatment (primary endpoint). Of the 35 of 40 randomized subjects who reached the day 28, 19% achieved a complete response (CR), 72% a partial response (PR), and 9% had stable disease (SD), resulting in an overall response rate (ORR) of 91%. During the 14-day placebo-controlled phase, greater improvement was measured in clinical disease and oral pain for clobetasol versus placebo. Although clobetasol solution was well-tolerated, day 28 cosyntropin testing demonstrated significant suppression of peak serum cortisol, indicating new adrenal insufficiency in 14 patients who were not already receiving supraphysiologic glucocorticoids. Paired oral mucosal biopsies from baseline and day 28 show reduction in the frequency of all T cells, including effector and proliferating T cells and a reduction in non-T cells with cytoplasmic IL-17, accompanied by reduced salivary IL-6 and CXCL10. These controlled study data demonstrate that 0.05% clobetasol oral rinse is clinically effective and induces measurable tissue-level immunologic changes in the treatment of oral GVHD, including among patients who failed clobetasol ointment. This trial was registered at www.clinicialtrials.gov as #NCT01557517.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. El Jurdi N, Leinbach LI, Curtis LM, et al. A randomized phase 2 placebo-controlled trial of clobetasol solution for oral chronic graft-versus-host disease therapy. Blood Adv. 2026. PMID: 42790417. doi:10.1182/bloodadvances.2026020880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。